孕产妇肥胖:胎儿大脑自和mTOR的子宫内性别特异性变化
Nana Merabova1, Lierni Ugartemendia2, Andrea G Edlow3
1Department of Family Medicine, Medical College of Wisconsin-Prevea, Green Bay, Wisconsin, USA.
Obesity (Silver Spring, Md.)
|April 22, 2024
概括
孕产妇的肥胖影响胎儿的大脑发育,特别是在男性中,通过改变自机制. 阿迪波内克丁可能在这些神经发育变化中发挥作用.
科学领域:
- 神经科学是一个神经科学.
- 发展生物学 发展生物学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 孕产妇肥胖很普遍,影响了近40%的美国生育年龄妇女.
- 在子宫内对母亲肥胖的暴露与不良的神经发育结果有关.
- 在人体样本中,这些影响背后的机制在很大程度上是未知的.
研究的目的:
- 研究暴露于母亲肥胖的人类胎儿神经发育结果的分子机制.
- 检查自和阿迪波内克丁信号通路的作用.
- 为了确定对子宫内肥胖原生环境的反应中的性别特异性差异.
主要方法:
- 一个匹配的病例控制研究,涉及选择性终止妊娠 (15-21周妊娠).
- 通过ELISA测量母亲的血腺素水平.
- 在胎儿大脑组织中对关键的自和mTOR途径基因 (ADIPOR1,ADIPOR2,MTOR,ATG5,ATG7,BECN1,MAP1LC3B) 的mRNA表达量的量化.
主要成果:
- 孕产妇的肥胖与男性胎儿大脑组织的自抑制有关 (MTOR增加,ATG5,ATG7,MAP1LC3B减少).
- 女胎儿没有显著的变化或趋势向增加自.
- 自基因BECN1在暴露于子宫内母亲肥胖的两性中都被下调.
结论:
- 新的证据表明,在子宫内母亲的肥胖严重影响人类的神经发育,特别是在男性中.
- 自分子机制的改变与这些影响有关.
- 亚迪波内克被认为是观察到的神经发育变化的潜在调解者.
更多相关视频
11:44A Primary Human Trophoblast Model to Study the Effect of Inflammation Associated with Maternal Obesity on Regulation of Autophagy in the Placenta
Published on: September 27, 2017
11.4K
05:17Author Spotlight: Enhancing the Offspring Health in Rats with Maternal Exercise During Pregnancy
Published on: April 5, 2024
749
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
01:07Teratogenicity
2.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K